<DOC>
	<DOCNO>NCT01689636</DOCNO>
	<brief_summary>Open-label , single-center , single-treatment group , baseline-controlled ( safety ) study safety biodistribution Technetium Tc 99m EC20 four normal subject four subject know suspected ovarian cancer .</brief_summary>
	<brief_title>Safety Biodistribution Technetium Tc 99m EC20 Normal Volunteers Ovarian Cancer Patients</brief_title>
	<detailed_description>This single-center , open-label evaluation single injection Tc 99m EC20 contain 0.1 mg EC20 label 15 - 20 mCi technetium-99m normal volunteer patient know suspected ovarian cancer . Two normal volunteer two patient also receive injection 0.25 - 2.0 mg folic acid 1 2 minute prior injection Tc 99m EC20 . Serial blood sample urine collect 24-hour period follow injection pharmacokinetic evaluation . Serial whole body image acquire 24-hour postdose period dosimetry evaluation . Safety monitor predose postdose physical examination , electrocardiogram ( ECGs ) , vital sign clinical laboratory evaluation . Adverse event monitor time signing Informed Consent 24 hour postdose .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Technetium Tc 99m-ethylenedicysteine</mesh_term>
	<criteria>All subject females 18 year age old meet follow criterion : 1 . The four normal subject normal , establish medical history , physical examination , laboratory data , include CBC , serum chemistry , urinalysis . 2 . The two subject obvious advanced stage ovarian cancer either histopathologically proven stage 3 4 disease clinically obvious disease define 2 follow 3 condition : ( 1 ) pelvic mass ( 2 ) omental `` caking '' , ( 3 ) ascites . 3 . Subjects newly diagnose , treatment refractory , recurrent disease . Subjects treatment na√Øve least 2 month since last nonsurgical treatment . Subjects normal kidney liver function . 4 . The two subject suspect ovarian cancer know mass . Subjects normal kidney liver function . 5 . Subjects provide inform consent prior enrollment . The following subject exclude : 1 . Subject pregnant breastfeeding . 2 . Subject simultaneously participate another investigative drug device study , complete followup phase previous study within 30 day prior enrollment study . 3 . Subject known history chronic abuse drug alcohol test positive prestudy urine drug abuse screen . 4 . Subject currently take folic acid supplement could stop take supplement period 3 day ( 2 day prior study one day last imaging procedure ) . 5 . Subject physical condition unsuitable radionuclide imaging . 6 . Subject administer another radiopharmaceutical would interfere assessment biodistribution Technetium Tc 99m EC20 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Ovarian Cancer</keyword>
</DOC>